Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $26,561.48 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the transaction, the insider now owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ocular Therapeutix Trading Down 2.9 %

NASDAQ OCUL traded down $0.28 on Wednesday, reaching $9.47. 225,924 shares of the company were exchanged, compared to its average volume of 1,829,172. Ocular Therapeutix, Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $11.77. The business’s fifty day moving average price is $9.92 and its 200 day moving average price is $8.19. The stock has a market capitalization of $1.49 billion, a P/E ratio of -7.39 and a beta of 1.26. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19.

Hedge Funds Weigh In On Ocular Therapeutix

Large investors have recently modified their holdings of the business. Atlas Capital Advisors LLC acquired a new position in Ocular Therapeutix during the 2nd quarter worth about $34,000. Amalgamated Bank raised its stake in Ocular Therapeutix by 37.9% during the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 1,015 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Ocular Therapeutix during the 3rd quarter worth approximately $70,000. Finally, Algert Global LLC purchased a new position in shares of Ocular Therapeutix during the 2nd quarter worth approximately $69,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Wall Street Analysts Forecast Growth

OCUL has been the topic of several research reports. Scotiabank initiated coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target on the stock. HC Wainwright raised their price target on Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, Robert W. Baird lowered their price target on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.